{"id":1436,"date":"2015-04-27T11:48:29","date_gmt":"2015-04-27T11:48:29","guid":{"rendered":"http:\/\/www.wi.rwth-aachen.de\/SmartMedCN\/?p=1436"},"modified":"2015-04-27T11:48:29","modified_gmt":"2015-04-27T11:48:29","slug":"gsk-completes-major-three-part-transaction-with-novartis","status":"publish","type":"post","link":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/2015\/04\/27\/gsk-completes-major-three-part-transaction-with-novartis\/","title":{"rendered":"GSK completes major three-part transaction with Novartis"},"content":{"rendered":"

GlaxoSmithKline plc (LSE\/NYSE: GSK) announces that its three-part transaction with Novartis has completed\u00a0on 2nd March. As a result of this transaction, GSK has acquired Novartis\u2019s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion; has created a new world-leading Consumer Healthcare joint venture with Novartis in which GSK will have majority control and an equity interest of 63.5%; and has divested its Oncology business for an aggregate cash consideration of $16 billion. (Source: GSK)<\/strong><\/p>\n

\u8bfa\u534e\u8ba1\u5212\u8c6a\u63b720-50\u4ebf\u7f8e\u5143\u7528\u4e8e\u517c\u5e76\u6536\u8d2d<\/h3>\n

\u6765\u6e90\uff1a\u751f\u7269\u8c37<\/p>\n

\u6838\u5fc3\u63d0\u793a\uff1a\u6b64\u524d\uff0c\u5236\u836f\u884c\u4e1a\u4e24\u5927\u5de8\u5934\u845b\u5170\u7d20\u53f2\u514b(GSK)\u548c\u8bfa\u534e(Novartis)\u8fbe\u6210\u4e86\u4e00\u9879\u4ef7\u503c220\u4ebf\u7f8e\u5143\u7684\u4e00\u7cfb\u5217\u8d44\u4ea7\u7f6e\u6362\u4ea4\u6613\uff0c\u5e76\u4e0e\u4eca\u5e74\u4e09\u6708\u4efd\u5706\u6ee1\u5b8c\u6210\uff0c\u6839\u636e\u534f\u8bae\uff0c\u8bfa\u534e\u4ee5160\u4ebf\u7f8e\u5143\u6536\u8d2d\u845b\u5170\u7d20\u53f2\u514b\u7684\u80bf\u7624\u4e1a\u52a1;\u845b\u5170\u7d20\u53f2\u514b\u5219\u521d\u6b65\u4ee552.5\u4ebf\u7f8e\u91d1\u6536\u8d2d\u8bfa\u534e\u75ab\u82d7\u4e1a\u52a1(\u4e0d\u5305\u62ec\u6d41\u611f\u75ab\u82d7)\u3002\u540c\u65f6\uff0c\u8bfa\u534eOTC\u4e1a\u52a1\u5c06\u4e0e\u845b\u5170\u7d20\u53f2\u514bConsumer Business\u4e1a\u52a1\u7ec4\u5efa\u5408\u8d44\u516c\u53f8\uff0c\u5176\u4e2d\u8bfa\u534e\u5360\u80a136.5%\uff0c\u845b\u5170\u7d20\u53f2\u514b\u5360\u80a163.5%\u3002<\/p>\n

\n

[hide for= “!logged”]<\/p>\n

\u5728\u751f\u7269\u533b\u836f\u4ea7\u4e1a\u4e2d\uff0c\u4f18\u5316\u91cd\u7ec4\u548c\u626c\u957f\u907f\u77ed\u662f\u751f\u7269\u533b\u836f\u516c\u53f8\u5728\u6fc0\u70c8\u7ade\u4e89\u4e2d\u751f\u5b58\u4e0b\u53bb\u6c38\u6052\u7684\u4e3b\u9898\u3002\u8fd9\u4e00\u5b9a\u5f8b\u540c\u6837\u9002\u7528\u4e8e\u5404\u5927\u751f\u7269\u533b\u836f\u5de8\u5934\u3002\u6b64\u524d\uff0c\u5236\u836f\u884c\u4e1a\u4e24\u5927\u5de8\u5934\u845b\u5170\u7d20\u53f2\u514b(GSK)\u548c\u8bfa\u534e(Novartis)\u8fbe\u6210\u4e86\u4e00\u9879\u4ef7\u503c220\u4ebf\u7f8e\u5143\u7684\u4e00\u7cfb\u5217\u8d44\u4ea7\u7f6e\u6362\u4ea4\u6613\uff0c\u5e76\u4e0e\u4eca\u5e74\u4e09\u6708\u4efd\u5706\u6ee1\u5b8c\u6210\uff0c\u6839\u636e\u534f\u8bae\uff0c\u8bfa\u534e\u4ee5160\u4ebf\u7f8e\u5143\u6536\u8d2d\u845b\u5170\u7d20\u53f2\u514b\u7684\u80bf\u7624\u4e1a\u52a1;\u845b\u5170\u7d20\u53f2\u514b\u5219\u521d\u6b65\u4ee552.5\u4ebf\u7f8e\u91d1\u6536\u8d2d\u8bfa\u534e\u75ab\u82d7\u4e1a\u52a1(\u4e0d\u5305\u62ec\u6d41\u611f\u75ab\u82d7)\u3002\u540c\u65f6\uff0c\u8bfa\u534eOTC\u4e1a\u52a1\u5c06\u4e0e\u845b\u5170\u7d20\u53f2\u514bConsumer Business\u4e1a\u52a1\u7ec4\u5efa\u5408\u8d44\u516c\u53f8\uff0c\u5176\u4e2d\u8bfa\u534e\u5360\u80a136.5%\uff0c\u845b\u5170\u7d20\u53f2\u514b\u5360\u80a163.5%\u3002\u8fd9\u4e00\u534f\u8bae\u7684\u5b8c\u6210\u65e0\u7591\u4f7f\u8bfa\u534e\u516c\u53f8\u548c\u845b\u5170\u7d20\u53f2\u514b\u516c\u53f8\u5728\u5404\u81ea\u9886\u5148\u7684\u9886\u57df\u4e2d\u8fdb\u4e00\u6b65\u589e\u5927\u4e86\u81ea\u5df1\u7684\u4f18\u52bf\u3002\u4e0d\u8fc7\uff0c\u4f3c\u4e4e\u8bfa\u534e\u516c\u53f8\u5e76\u4e0d\u8ba4\u4e3a\u53ef\u4ee5\u5c31\u6b64\u9ad8\u6795\u65e0\u5fe7\u3002<\/p>\n

\u5728\u4e0e\u845b\u5170\u7d20\u53f2\u514b\u516c\u53f8\u5b8c\u6210\u4e86\u8fd9\u9879\u610f\u4e49\u91cd\u5927\u7684\u8d44\u4ea7\u5bf9\u6362\u534f\u8bae\u540e\uff0c\u8bfa\u534e\u516c\u53f8 CEO Joe Jimenez\u8868\u793a\u516c\u53f8\u5c06\u7ee7\u7eed\u5728\u517c\u5e76\u6536\u8d2d\u9886\u57df\u5927\u5c55\u62f3\u811a\u3002\u6240\u8c13\u5175\u9a6c\u672a\u52a8\u7cae\u8349\u5148\u884c\uff0cJoe Jimenez\u8868\u793a\u5df2\u7ecf\u7ed9\u91cd\u65b0\u56de\u5230\u6536\u8d2d\u8c08\u5224\u684c\u65c1\u7684\u8bfa\u534e\u516c\u53f8\u51c6\u5907\u4e8620-50\u4ebf\u7f8e\u5143\u7684\u6536\u8d2d\u4e13\u9879\u8d44\u91d1\u3002\u8fd9\u4e9b\u4e0d\u80fd\u4e0d\u4f7f\u4f17\u591a\u534e\u5c14\u8857\u7684\u5206\u6790\u4eba\u58eb\u63d0\u51fa\u7591\u95ee\uff1a\u672a\u6765\u6570\u6708\u53c8\u6709\u54ea\u4e9b\u516c\u53f8\u5c06\u88ab\u8d34\u4e0a\u8bfa\u534e\u516c\u53f8\u7684\u6807\u7b7e?<\/p>\n

\u968f\u7740\u751f\u7269\u533b\u836f\u7814\u7a76\u6210\u672c\u7684\u4e0d\u65ad\u589e\u52a0\uff0c\u8d8a\u6765\u8d8a\u591a\u7684\u751f\u7269\u533b\u836f\u516c\u53f8\u5f00\u59cb\u901a\u8fc7\u6536\u8d2d\u517c\u5e76\u7684\u65b9\u5f0f\u6765\u83b7\u5f97\u4f18\u8d28\u7684\u836f\u7269\u7814\u53d1\u9879\u76ee\u4ee5\u53ca\u589e\u52a0\u516c\u53f8\u7684\u521b\u65b0\u80fd\u529b\u3002\u53e6\u4e00\u65b9\u9762\uff0c\u4f17\u591a\u7545\u9500\u836f\u7269\u4e13\u5229\u60ac\u5d16\u5230\u6765\u4e5f\u589e\u52a0\u4e86\u751f\u7269\u533b\u836f\u516c\u53f8\u7684\u5371\u673a\u610f\u8bc6\u3002\u800c\u8bfa\u534e\u516c\u53f8\u6b64\u6b21\u6536\u8d2d\u6fc0\u60c5\u4ecd\u65e7\u4e5f\u662f\u8fd9\u4e00\u8d8b\u52bf\u7684\u751f\u52a8\u5199\u7167\u3002<\/p>\n

[\/hide]<\/p>\n

\n","protected":false},"excerpt":{"rendered":"

GlaxoSmithKline plc (LSE\/NYSE: GSK) announces that its three-part transaction with Novartis has completed\u00a0on 2nd March. As a result of this transaction, GSK has acquired Novartis\u2019s global Vaccines business (excluding influenza […]<\/p>\n","protected":false},"author":1001,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"c2c_always_allow_admin_comments":false,"footnotes":""},"categories":[5],"tags":[7,24],"class_list":["post-1436","post","type-post","status-publish","format-standard","hentry","category-pharmaceutical-company-news","tag-consolidation","tag-pharmacy-management"],"_links":{"self":[{"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/posts\/1436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/users\/1001"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/comments?post=1436"}],"version-history":[{"count":0,"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/posts\/1436\/revisions"}],"wp:attachment":[{"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/media?parent=1436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/categories?post=1436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.rwth-aachen.de\/smartmedcn\/wp-json\/wp\/v2\/tags?post=1436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}